Aptevo Therapeutics Inc. (APVO)

Aptevo Therapeutics emerged from Seattle as a focused immunotherapy startup in 2016, born into a biotech landscape already crowded with cancer-fighting approaches but still hungry for novel angles on immune activation. The company started with a specific insight: instead of trying to outsmart cancer’s defenses head-on, what if you could redirect the patient’s own T cells to recognize and destroy leukemia? That question became Aptevo’s founding premise—and it shaped everything that followed.

The early years were defined by platform development. Aptevo built its ADAPTIR technology, a platform designed to create bispecific molecules (proteins that can bind two targets simultaneously) with precision. The real innovation wasn’t just making bispecifics; it was making them with the safety and manufacturability profiles that pharma companies actually need. Mipletamig, the company’s lead molecule, represents the maturation of that thinking—a CD3xCD123 bispecific engineered to bridge T cells and leukemia cells expressing the CD123 surface marker, effectively recruiting immune firepower to cells that would otherwise escape notice.

By 2025 and into 2026, mipletamig had reached the moment that defines a clinical-stage biotech. Phase 1b/2 data from the RAINIER trial showed an 86% clinical benefit rate in newly diagnosed AML patients, with no cytokine release syndrome observed—a crucial safety milestone in a field where T cell activation can turn dangerous fast. More compellingly, 100% of patients in one cohort achieved remission within 30 days. These numbers don’t guarantee anything, but they moved Aptevo from “hopeful startup” to “company with a real shot at an approval.” In March 2026, the company reported its results openly and began pivoting toward the next phase of development.

What distinguishes Aptevo now is not just mipletamig but the broader platform momentum. The company is advancing preclinical trispecific candidates (molecules that bind three targets instead of two), expanding the AML program while exploring applications in acute lymphoblastic leukemia, and building a pipeline beyond the single-molecule bet. A $60 million equity line of credit announced in January 2026 signaled confidence from the capital markets and provided a financial runway into 2029—enough oxygen to move through later-stage testing without the perpetual cash crisis that haunts many clinical biotechs.

The leadership transition in April 2026, with Marvin White moving to Executive Chair and Jeff Lamothe becoming President and CEO, represented a recalibration familiar in biotech: moving from founder-era management to seasoned operational leadership as the company approaches inflection points. Whether mipletamig reaches patients or becomes a case study in clinical failure, Aptevo has already answered its first hard question—whether its platform could generate clinically meaningful signals. The next question is whether it can scale them into commercial reality.